文献速递免疫规划传染病防控与疫情报告

动物模型中的安全性和免疫原性研究支持植物生产的双价诺如病毒样颗粒疫苗的临床开发

Safety and immunogenicity studies in animal models support clinical development of a bivalent norovirus-like particle vaccine produced in plants.
PubMed 文献 · Vaccine · 2022-01-19

诺如病毒是全球流行性急性胃肠炎的主要病因,儿童和老年人尤其易感。研究用植物表达系统生产GI.4和GII.4病毒样颗粒,按1:1混合成双价疫苗rNV-2v,在新西兰白兔中皮下或肌内接种,未加佐剂即诱导强基因群特异性免疫应答,局部刺激可自行消退,无全身毒性,支持启动临床开发。

要点

  • rNV-2v由GI.4和GII.4病毒样颗粒按1:1(w/w)混合而成,用植物表达系统生产。
  • 新西兰白兔皮下或肌内接种200至400 μg VLP/次,未加佐剂即诱导强基因群特异性免疫应答。
  • 3次接种方案中,皮下或肌内途径的NOAEL最初为200 μg,改用改良GI.4 VLP后肌内途径升至300 μg。

核心结论

  • 植物生产的双价诺如病毒疫苗rNV-2v在兔中安全且免疫原性强,支持启动临床开发。

研究设计与样本

  • 一项试点研究和两项符合GLP规范的毒性研究,在新西兰白兔中皮下或肌内接种rNV-2v。

主要发现

  • 不同剂量(200至400 μg VLP/次)和接种程序(第1天和第7天;或第1、15、29天)未加佐剂即诱导强基因群特异性免疫应答。
  • 注射部位偶发局部刺激,随时间消退,为非不良性,与预期反应原性一致。
  • 与溶媒对照组相比,临床化学、血液学、器官重量、大体检查或组织病理学均未见疫苗相关全身毒性迹象。
  • 3次接种方案(n+1临床方案)中,皮下或肌内途径的NOAEL最初确定为200 μg;改良GI.4 VLP与野生型GII.4 VLP按1:1(w/w)混合后,肌内途径更高剂量下NOAEL升至300 μg。
  • 两项毒性研究的血清学显示,肌内或皮下接种rNV-2v均产生显著且大幅度的抗VLP特异性抗体滴度,以及相关诺如病毒阻断抗体应答。

关键数值与推荐

  • rNV-2v由GI.4和GII.4病毒样颗粒按1:1(w/w)混合而成。
  • 未加佐剂,剂量范围200至400 μg VLP/次,接种程序为第1天和第7天或第1、15、29天。
  • 3次接种方案中,皮下或肌内途径的NOAEL最初为200 μg;改良GI.4 VLP与野生型GII.4 VLP按1:1(w/w)混合后肌内途径NOAEL升至300 μg。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Noroviruses (NoV) are the leading cause of epidemic acute gastroenteritis in humans worldwide. A safe and effective vaccine that prevents NoV infection or minimizes NoV disease burden is needed, especially for children and the elderly who are particularly susceptible to NoV disease. A plant-based expression system (magnICON®) was used to manufacture two different virus-like particle (VLP) immunogens derived from human NoV genogroups I and II, genotype 4 (GI.4 and GII.4), which were subsequently blended 1:1 (w/w) into a bivalent vaccine composition (rNV-2v). Here, we report on the safety and immunogenicity of rNV-2v from one pilot and two GLP-compliant toxicity studies in New Zealand White rabbits administered the vaccine subcutaneously (SC) or intramuscularly (IM). Strong genogroup-specific immune responses were induced by vaccination without adjuvant at various doses (200 to 400 μg VLP/administration) and administration schedules (Days 1 and 7; or Days 1, 15 and 29). The results showed sporadic local irritation at the injection site, which resolved over time, and was non-adverse and consistent with expected reactogenicity. There were no signs of systemic toxicity related to vaccine administration relative to vehicle-treated controls with respect to clinical chemistry, haematology, organ weights, macroscopic examinations, or histopathology. In a 3-administration regimen (n + 1 the clinical regimen), the NOAEL for rNV-2v via the SC or IM route was initially determined to be 200 μg. An improved GI.4 VLP variant mixed 1:1 (w/w) with the wild-type GII.4 VLP was subsequently evaluated via the IM route at a higher dose in the same 3-administration model, and the NOAEL was raised to 300 µg. Serology performed in samples of both toxicity studies showed significant and substantial anti-VLP-specific antibody titers for rNV-2v vaccines administered via the IM or SC route, as well as relevant NoV blocking antibody responses. These results support initiation of clinical development of the plant-made NoV vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tusé D, Malm M, Tamminen K, et al. Safety and immunogenicity studies in animal models support clinical development of a bivalent norovirus-like particle vaccine produced in plants. Vaccine. 2022. PMID: 35063285. doi:10.1016/j.vaccine.2022.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。